Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178903 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL2186103 | 0.86 | CYP2C19 (0.51) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL1895209 | 0.85 | CYP2C19 (0.57) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL109226 | 0.85 | CYP2C19 (0.57) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL2184431 | 0.82 | ALDH1A1 (0.54) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL12094206 | 0.82 | CYP2C19 (0.54) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL2711223 | 0.77 | CYP2C19 (0.54) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL12526245 | 0.77 | CYP2C19 (0.50) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL8927381 | 0.77 | MAPT (0.53) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT | |
| SCHEMBL5585028 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CYP2C19CYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | PROTAMED, INC. | 2012-03-08 | — | — | US | disclosed |
| US-7919530-B2 | Compounds, compositions, and methods for the treatment of synucleinopathies | PROTEOTECH, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100179223-A1 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies | PROTAMED, INC. | 2010-07-15 | — | — | US | disclosed |
| US-7714170-B2 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTAMED, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179223-A1 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies | SNCA, PARK7, COMT | ALDH1A1 2390/4885CYP2C19 2083/4885CYP1A2 3165/4885 |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | NR1H2, NR1H3, MSR1 | ALDH1A1 2018/4885CYP2C19 2208/4885CYP1A2 801/4885 |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | APP, BACE1, BACE2 | ALDH1A1 2275/4885CYP2C19 1752/4885CYP1A2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.